VITAL Findings — A Decisive Verdict on Vitamin D Supplementation
- 28 July 2022
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 387 (4) , 368-370
Abstract
An estimated one third or more of U.S. adults 60 years of age or older take vitamin D supplements, not including those who take multivitamins or other compounds containing vitamin D.1 Yet controversy continues about its overall benefits. In this issue of the Journal, LeBoff and colleagues2 report findings from an ancillary study of the Vitamin D and Omega-3 Trial (VITAL),3 which extend the results of that trial; taken together, VITAL and this ancillary study show that vitamin supplements do not have important health benefits in the general population of older adults, even in those with low 25-hydroxyvitamin D levels.Keywords
This publication has 7 references indexed in Scilit:
- Supplemental Vitamin D and Incident Fractures in Midlife and Older AdultsNew England Journal of Medicine, 2022
- Effect of vitamin D and/or omega‐3 fatty acid supplementation on stroke outcomes: A randomized trialEuropean Journal of Neurology, 2020
- VITamin D and OmegA-3 TriaL (VITAL): Effects of Vitamin D Supplements on Risk of Falls in the US PopulationThe Journal of Clinical Endocrinology & Metabolism, 2020
- Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trialsThe Journal of Steroid Biochemistry and Molecular Biology, 2020
- Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone StrengthJAMA, 2019
- Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and CancerNew England Journal of Medicine, 2019
- The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular diseaseContemporary Clinical Trials, 2012